Navigation path

Additional tools



    Profile of registrant

International Drug Policy Consortium

Identification number in the register: 75318797051-52
Registration date: 01/11/2011 17:02:21

The information on this entity was last modified on: 06/10/2014 12:00:20
The date of the last annual update was: 06/10/2014 12:00:20

This entry follows the format of the previous Register. It will be changed to the new format when the entity makes the next update.
Next update due latest on: 27/04/2015

    Registrant : Organisation or self-employed individual

International Drug Policy Consortium

IDPC

Company limited by guarantee

    Section of registration

III - Non-governmental organisations

Non-governmental organisations, platforms and networks and similar

    Contact details

City Road, 5th Floor, 124-128
London EC1V 2NJ
UNITED KINGDOM

(+44) 2073242975

(+44) 2073242977

IDPC is a global network of NGOs and professional networks that come together to promote objective and open debate on drug policy issues at the national and international level. We support evidence-based policies that are effective in reducing drug-related harm.

IDPC’s vision is that national and international drug policies are grounded in the principles of human rights and human security, social inclusion, public health, development and civil society engagement.

IDPC intervenes at two levels in the decision making process: We facilitate networking and collaboration between civil society stakeholders, and seek to empower civil society and the most affected populations to better engage with and influence policy making processes. In parallel, IDPC also intervenes directly with high-level policy making processes by providing analysis and expertise to governments and UN agencies on effective and more humane drug policy options.

IDPC members promote the following policy principles in our advocacy work with national governments and international agencies:
1. Drug policies should be developed through a structured and objective assessment of priorities and evidence.
2. All activities should be undertaken in full compliance with international human rights law.
3. Drug policies should focus on reducing the harmful consequences rather than the scale of drug use and markets.
4. Policy and activities should seek to promote the social inclusion of marginalised groups, and not focus on punitive measures towards them.
5. Governments should build open and constructive relationships with civil society in the discussion and delivery of their strategies.

    Person with legal responsibility

Ms  Ann Fordham

Executive Director

    Person in charge of EU relations

Mr  Mike Trace

Chair

    Goals / remit

IDPC is a a global network of NGOs and professional networks that come together to promote objective and open debate on drug policy issues at the national and international level. We support evidence-based policies that are effective in reducing drug-related harm.

IDPC produces briefing papers, disseminates the reports of its member organisations about particular drug-related matters, and offers expert advice to policy makers and officials around the world.

IDPC members have a wide range of experience and expertise in the analysis of drug problems and policies, and have contributed to policy debates at national and international level.

We have two main objectives:
- We provide channels for grassroots organisations to better engage with policy making processes: we facilitate communication and cooperation between civil society stakeholders, and we produce and disseminate information and materials on more effective and humane drug policies, that national and local NGOs can use in their own work. We also organise capacity building trainings to support the drug policy advocacy work of NGOs. In order to facilitate civil society engagement, we organise our work regionally.

- We draw on the knowledge within our network to offer expert advice to policy makers on how best to review their drug policies at the national and international level. The IDPC network includes many individuals who have experience of creating or reviewing government drug policies and strategies, and these individuals are available to engage in high-level discussions with policy makers.

  • European
  • global
  • national

    Activities

Over the past three years, under grants from the European Commission Drug Prevention and Information Programme, IDPC conducted a number of activities across Europe, in collaboration with key NGO partners.

In 2010-2011, IDPC supported the creation of a dynamic network of NGOs from South East Europe to promote exchange of information and experience among professionals in the field of drug policy in the region. We also produced a number of publications focused on South East Europe and Western European countries.

Since April 2011, IDPC has been involved in a project funded by the European Commission in collaboration with the Transnational Institute and other European NGOs. This project aims to promote exchange of experience through informal drug policy dialogues, expert seminars and the drafting of expert publications on issues related to the European Union and European countries.

IDPC also shares evidence and best practice from the EU and its member states in international forums, such as the Commission on Narcotic Drugs (CND), through the organisation of side events, the dissemination of materials and direct meetings with government delegations.

IDPC is also an active member of the European Commission Civil Society Forum on Drugs where we have engaged in drug policy debates regarding the European Union Drug Strategy and its Action Plans. Individually, IDPC has also watched closely the drafting of the new EU Drug Strategy for 2013-2020 and the Action Plan for 2013-2016. We has provided a set of recommendations, as well as organised a seminar at the European Parliament in May 2012 to ensure open discussions among representatives of EU institutions and international experts on the direction of EU drug policy for the coming years.

Today, IDPC is engaged in offering recommendations to the European Commission, in particular the Horizontal Drugs Group, on key aspects of European Drug Policy and strategic positions in the lead up to the United Nations General Assembly Special Session on Drugs (UNGASS) to be held in 2016.

    Number of persons involved in the activities described in the box above

9

IDPC staff includes five full time and one part-time staff members. We also hire consultants around the world who work on thematic or regional issues related to drug policy. For more information on the IDPC team, please visit: www.idpc.net/team.

    Persons accredited for access to European Parliament premises

No accredited persons

    Fields of interest

  • Communication
  • Development
  • External Relations
  • Home Affairs
  • Justice and Fundamental Rights
  • Public Health
  • Regional Policy
  • Trans-European Networks
  • Youth

    Membership and affiliation

120

  • BELGIUM
  • BULGARIA
  • CROATIA
  • DENMARK
  • FRANCE
  • GERMANY
  • GREECE
  • HUNGARY
  • IRELAND
  • ITALY
  • LITUANIA
  • NETHERLANDS
  • POLAND
  • PORTUGAL
  • ROMANIA
  • SLOVENIA
  • SPAIN
  • SWEDEN
  • UNITED KINGDOM
  • ALBANIA
  • ARGENTINA
  • AUSTRALIA
  • BOLIVIA
  • BOSNIA-HERZEGOVINA
  • BRAZIL
  • CANADA
  • CHILE
  • COLOMBIA
  • COSTA RICA
  • DOMINICAN REPUBLIC
  • EL SALVADOR
  • GEORGIA
  • INDIA
  • INDONESIA
  • KENYA
  • LEBANON
  • LIBERIA
  • MACEDONIA, FORMER YUGOSLAV REPUBLIC OF
  • MALAYSIA
  • MAURITIUS
  • MEXICO
  • MONTENEGRO
  • NEW ZEALAND
  • PALESTINIAN OCCUPIED TERRITORY
  • PERU
  • PUERTO RICO
  • RUSSIA, FEDERATION OF
  • SAINT LUCIA
  • SERBIA
  • SWITZERLAND
  • THAILAND
  • TUNISIA
  • TURKEY
  • UGANDA
  • UNITED ARAB EMIRATES
  • UNITED STATES
  • URUGUAY
  • VIETNAM
  • ZIMBABWE

IDPC is a member of the European Civil Society Forum on Drugs, and of the Vienna NGO Committee on Drugs. IDPC is now also a member of the New York NGO Committee on Drugs.

    Financial data

04/2013  -  03/2014

963,781 €

364,645 €

 €

126,753 €

237,892 €

 €

599,136 €

 €

 €

599,136 €

100,000  € - 150,000  €

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.